Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 41 | 2025 | 5097 | 1.820 |
Why?
|
| Anti-HIV Agents | 19 | 2025 | 1324 | 1.600 |
Why?
|
| Homosexuality, Male | 10 | 2024 | 52 | 1.480 |
Why?
|
| Transgender Persons | 10 | 2024 | 24 | 1.410 |
Why?
|
| Pre-Exposure Prophylaxis | 7 | 2025 | 196 | 1.080 |
Why?
|
| Sexual and Gender Minorities | 8 | 2024 | 29 | 1.000 |
Why?
|
| Anti-Retroviral Agents | 9 | 2019 | 551 | 0.790 |
Why?
|
| HIV-1 | 12 | 2022 | 1260 | 0.760 |
Why?
|
| Pyridones | 5 | 2022 | 100 | 0.690 |
Why?
|
| Tenofovir | 4 | 2024 | 171 | 0.670 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2024 | 256 | 0.630 |
Why?
|
| Female | 42 | 2025 | 9103 | 0.630 |
Why?
|
| Male | 34 | 2024 | 6754 | 0.570 |
Why?
|
| Adult | 31 | 2025 | 5913 | 0.570 |
Why?
|
| Viral Load | 15 | 2021 | 819 | 0.540 |
Why?
|
| Humans | 45 | 2025 | 14537 | 0.530 |
Why?
|
| Disease Transmission, Infectious | 4 | 2018 | 39 | 0.530 |
Why?
|
| Drug Resistance, Viral | 5 | 2021 | 278 | 0.520 |
Why?
|
| HIV | 6 | 2021 | 380 | 0.510 |
Why?
|
| Young Adult | 18 | 2025 | 2498 | 0.500 |
Why?
|
| Sexual Partners | 3 | 2024 | 215 | 0.450 |
Why?
|
| Adolescent | 13 | 2025 | 2985 | 0.370 |
Why?
|
| CD4 Lymphocyte Count | 11 | 2017 | 656 | 0.360 |
Why?
|
| Cohort Studies | 10 | 2024 | 967 | 0.330 |
Why?
|
| HIV Seropositivity | 4 | 2022 | 265 | 0.330 |
Why?
|
| Africa South of the Sahara | 7 | 2024 | 353 | 0.310 |
Why?
|
| Sexual Behavior | 4 | 2024 | 320 | 0.300 |
Why?
|
| Secondary Prevention | 2 | 2018 | 20 | 0.290 |
Why?
|
| Medication Adherence | 2 | 2025 | 151 | 0.270 |
Why?
|
| Treatment Outcome | 9 | 2021 | 889 | 0.270 |
Why?
|
| Social Stigma | 3 | 2024 | 80 | 0.260 |
Why?
|
| Malawi | 6 | 2021 | 87 | 0.250 |
Why?
|
| Bisexuality | 1 | 2024 | 3 | 0.240 |
Why?
|
| Coinfection | 2 | 2017 | 276 | 0.240 |
Why?
|
| Patient Preference | 1 | 2025 | 30 | 0.240 |
Why?
|
| HIV Antibodies | 2 | 2017 | 247 | 0.230 |
Why?
|
| Risk Factors | 8 | 2022 | 1475 | 0.220 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2017 | 195 | 0.220 |
Why?
|
| Counseling | 1 | 2024 | 143 | 0.220 |
Why?
|
| Prospective Studies | 6 | 2025 | 1160 | 0.210 |
Why?
|
| South Africa | 15 | 2021 | 7596 | 0.200 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2017 | 324 | 0.200 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 8 | 0.200 |
Why?
|
| Qualitative Research | 1 | 2024 | 321 | 0.200 |
Why?
|
| Papillomavirus Vaccines | 1 | 2022 | 18 | 0.190 |
Why?
|
| Superinfection | 1 | 2021 | 8 | 0.190 |
Why?
|
| Chlamydia Infections | 1 | 2021 | 17 | 0.190 |
Why?
|
| Gonorrhea | 1 | 2021 | 20 | 0.190 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 74 | 0.180 |
Why?
|
| Kenya | 4 | 2024 | 183 | 0.180 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 57 | 0.180 |
Why?
|
| Patient Selection | 1 | 2020 | 40 | 0.180 |
Why?
|
| Patient Participation | 1 | 2020 | 13 | 0.180 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2021 | 103 | 0.170 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2020 | 33 | 0.170 |
Why?
|
| Weight Gain | 1 | 2020 | 77 | 0.160 |
Why?
|
| Continuity of Patient Care | 1 | 2019 | 33 | 0.160 |
Why?
|
| Prevalence | 5 | 2022 | 1192 | 0.160 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 106 | 0.160 |
Why?
|
| Disclosure | 1 | 2019 | 25 | 0.160 |
Why?
|
| Double-Blind Method | 4 | 2020 | 272 | 0.160 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 1 | 2018 | 24 | 0.160 |
Why?
|
| Disease Progression | 5 | 2017 | 154 | 0.150 |
Why?
|
| Drug Utilization | 1 | 2018 | 10 | 0.150 |
Why?
|
| Drug Administration Schedule | 5 | 2018 | 156 | 0.150 |
Why?
|
| Self Report | 1 | 2019 | 114 | 0.150 |
Why?
|
| Health Personnel | 1 | 2020 | 231 | 0.150 |
Why?
|
| Middle Aged | 7 | 2020 | 3601 | 0.150 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2021 | 472 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 42 | 0.150 |
Why?
|
| Serologic Tests | 1 | 2017 | 26 | 0.140 |
Why?
|
| Pleural Cavity | 1 | 2017 | 7 | 0.140 |
Why?
|
| Radiography | 1 | 2017 | 80 | 0.140 |
Why?
|
| Chemoprevention | 1 | 2017 | 33 | 0.140 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 529 | 0.140 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2017 | 118 | 0.140 |
Why?
|
| Hepatitis B | 1 | 2017 | 125 | 0.130 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2018 | 472 | 0.130 |
Why?
|
| Hepatitis B virus | 1 | 2017 | 157 | 0.130 |
Why?
|
| Drug Monitoring | 2 | 2018 | 55 | 0.120 |
Why?
|
| Longitudinal Studies | 3 | 2025 | 435 | 0.120 |
Why?
|
| HIV-2 | 1 | 2015 | 15 | 0.120 |
Why?
|
| HIV Seronegativity | 1 | 2015 | 52 | 0.120 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2014 | 187 | 0.120 |
Why?
|
| Brazil | 3 | 2020 | 47 | 0.120 |
Why?
|
| Africa | 3 | 2025 | 376 | 0.120 |
Why?
|
| Treatment Failure | 4 | 2018 | 175 | 0.120 |
Why?
|
| Placebos | 3 | 2020 | 44 | 0.120 |
Why?
|
| HIV Protease Inhibitors | 1 | 2015 | 92 | 0.120 |
Why?
|
| Administration, Oral | 2 | 2025 | 127 | 0.120 |
Why?
|
| Mutation | 1 | 2015 | 306 | 0.110 |
Why?
|
| BCG Vaccine | 1 | 2011 | 20 | 0.100 |
Why?
|
| Antibodies, Bacterial | 1 | 2012 | 153 | 0.090 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2011 | 33 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 370 | 0.090 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 112 | 0.090 |
Why?
|
| Infant | 5 | 2015 | 2244 | 0.090 |
Why?
|
| Injections | 2 | 2020 | 31 | 0.090 |
Why?
|
| Pneumococcal Vaccines | 1 | 2012 | 278 | 0.080 |
Why?
|
| Pneumococcal Infections | 1 | 2012 | 299 | 0.080 |
Why?
|
| United States | 2 | 2020 | 132 | 0.080 |
Why?
|
| Incidence | 2 | 2021 | 685 | 0.080 |
Why?
|
| Infant, Newborn | 3 | 2022 | 1479 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 1422 | 0.080 |
Why?
|
| Mass Screening | 2 | 2021 | 245 | 0.070 |
Why?
|
| Time Factors | 3 | 2015 | 507 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 262 | 0.070 |
Why?
|
| Genotype | 2 | 2018 | 442 | 0.070 |
Why?
|
| Pregnancy | 2 | 2022 | 1862 | 0.060 |
Why?
|
| India | 2 | 2017 | 62 | 0.060 |
Why?
|
| Intention to Treat Analysis | 2 | 2016 | 21 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 106 | 0.060 |
Why?
|
| Aged | 2 | 2020 | 1740 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2019 | 799 | 0.060 |
Why?
|
| Condoms | 1 | 2024 | 88 | 0.060 |
Why?
|
| Risk-Taking | 1 | 2024 | 121 | 0.060 |
Why?
|
| Point-of-Care Systems | 1 | 2024 | 91 | 0.060 |
Why?
|
| Point-of-Care Testing | 1 | 2024 | 71 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 150 | 0.060 |
Why?
|
| Child | 2 | 2022 | 2242 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2024 | 203 | 0.050 |
Why?
|
| Diketopiperazines | 1 | 2022 | 6 | 0.050 |
Why?
|
| Emtricitabine | 1 | 2022 | 78 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 563 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2022 | 34 | 0.050 |
Why?
|
| Chlamydia trachomatis | 1 | 2021 | 13 | 0.050 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2021 | 15 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2021 | 35 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2021 | 89 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 171 | 0.040 |
Why?
|
| Phylogeny | 1 | 2021 | 231 | 0.040 |
Why?
|
| Fear | 1 | 2020 | 11 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2022 | 480 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 101 | 0.040 |
Why?
|
| Depression | 1 | 2021 | 121 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 365 | 0.040 |
Why?
|
| Professional Practice Gaps | 1 | 2019 | 2 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2018 | 31 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 34 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 68 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2018 | 5 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 6 | 0.040 |
Why?
|
| Research | 1 | 2019 | 65 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 38 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2017 | 10 | 0.040 |
Why?
|
| Thailand | 1 | 2017 | 26 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2017 | 23 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2018 | 225 | 0.040 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2017 | 48 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 280 | 0.040 |
Why?
|
| Virology | 1 | 2017 | 13 | 0.040 |
Why?
|
| Immunoassay | 1 | 2017 | 28 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2018 | 198 | 0.030 |
Why?
|
| Asia | 1 | 2017 | 72 | 0.030 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2017 | 47 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 217 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2016 | 21 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 188 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 87 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 385 | 0.030 |
Why?
|
| Chromatography, Affinity | 1 | 2015 | 8 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2015 | 60 | 0.030 |
Why?
|
| Genome, Viral | 1 | 2015 | 64 | 0.030 |
Why?
|
| AIDS Serodiagnosis | 1 | 2015 | 44 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 181 | 0.030 |
Why?
|
| Aging | 1 | 2015 | 109 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2014 | 18 | 0.030 |
Why?
|
| Gross Domestic Product | 1 | 2013 | 2 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 27 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 163 | 0.030 |
Why?
|
| Opsonin Proteins | 1 | 2012 | 4 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2012 | 15 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2013 | 115 | 0.030 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2012 | 42 | 0.030 |
Why?
|
| Neoplasms | 1 | 2014 | 147 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 253 | 0.020 |
Why?
|
| Lymphadenitis | 1 | 2011 | 2 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 139 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 237 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2015 | 1748 | 0.020 |
Why?
|
| Physicians | 1 | 2010 | 31 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2011 | 303 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 279 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1992 | 17 | 0.010 |
Why?
|
| African Americans | 1 | 1992 | 47 | 0.010 |
Why?
|
| Health Education | 1 | 1992 | 35 | 0.010 |
Why?
|
| Family Planning Services | 1 | 1992 | 46 | 0.010 |
Why?
|
| Urban Population | 1 | 1992 | 257 | 0.010 |
Why?
|